Olendalizumab

Names

[ CAS No. ]:
2210314-30-8

[ Name ]:
Olendalizumab

Biological Activity

[Description]:

Olendalizumab (ALXN1007) is a mouse-derived and humanized IgG2-G4-κ antibody, targeting to Complement protein C5a (Ki=60 pM). Olendalizumab targets the complement inflammatory pathway. Moreover, Olendalizumab can be used for research of complement mediated disorder caused by corona virus[1][2].

[Related Catalog]:

Research Areas >> Infection
Signaling Pathways >> Immunology/Inflammation >> Complement System

[Target]

Complement protein C5a[1]


[In Vitro]

Olendalizumab 可用作生物素化捕获试剂，在 Bioaffy wash 1 中的工作浓度为 100 μg/mL，同时 AlexaFluor 标记的抗 C5a 克隆 2942 在 Rexxip F 中的工作浓度为 4 μg/mL[1]。 补体系统的成员，如 C3、C5a、C5b-9，包括受体，如 C3aR 和 C5aR，介导病毒感染后的肺损伤。 此外，C5/C5a 更是冠状病毒引起的肺损伤中的非沉默补体。Olendalizumab 是有效的 C5a 抑制剂[2]。

[References]

[1]. Dysinger M, et al. A Gyrolab Assay for the Quantitation of Free Complement Protein C5a in Human Plasma. AAPS J. 2018 Oct 2;20(6):106.  

[2]. Annane D, et al. Methods for treating a complement mediated disorder caused by viruses. World Intellectual Property Organization, WO2021211940 A1. 2021-10-21.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds